Diaceutics (LON:DXRX) Reaches New 52-Week High – Still a Buy?

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as GBX 193 and last traded at GBX 185.86, with a volume of 1030922 shares traded. The stock had previously closed at GBX 186.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of GBX 215.

Diaceutics Stock Down 0.1%

The stock’s 50-day moving average price is GBX 145.97 and its 200-day moving average price is GBX 150.95. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85. The stock has a market cap of £157.72 million, a price-to-earnings ratio of 1,689.61 and a beta of 0.88.

Diaceutics (LON:DXRX) last issued its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. On average, sell-side analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.